Ratings Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:16:05 2025-03-17 am EDT			5-day change	1st Jan Change
588.25 ^DKK	+0.47%		+15.47%	-18.10%

Mar. 13	DNB raises target price for Zealand Pharma to DKK 1,150 (1,010), reiterates Buy - BN	FW
Mar. 13	Swiss stocks - Factors to watch on March 13	RE

Summary: Zealand Pharma A/S

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Highlights: Zealand Pharma A/S

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Zealand Pharma A/S

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's earnings releases usually do not meet expectations.

Ratings Chart: Zealand Pharma A/S

Source: Surperformance

ESG chart: Zealand Pharma A/S

Source: MSCI

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals	Valuation	Capi.($)
ZEALAND PHARMA A/S	-	-	6.03B
VERTEX PHARMACEUTICALS INCORPORATED			130B
REGENERON PHARMACEUTICALS, INC.			71.37B
BEIGENE, LTD.			27.77B
WUXI APPTEC CO., LTD.			25.3B
WUXI BIOLOGICS (CAYMAN) INC.			14.05B
Average			45.69B
Weighted average by Cap.

See all sector ratings

Investor

Trader

ESG MSCI

BBB

Financials

Sales growth

EPS Growth

Profitability

Net margin

Financial Health

Valuation

P/E ratio

EV/REVENUE

EV/EBITDA

PBR

Yield

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analysts' recommendations

4m Revision of opinion

Potential Price Target

4m Target Price Revision

12m Target Price Revision

Business Predictability

Earnings quality

Analyst Coverag

Divergence of analysts' recommendations

Divergence of Target Price

Divergence of analysts' opinions

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes